@Article{,
AUTHOR = {Jack Barkin},
TITLE = {Risks, benefits, and approaches to hormonal blockade in prostate cancer<br/>Highlights from the European Association of Urology  Meeting, March 20-24, 2015, Madrid, Spain},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {22},
YEAR = {2015},
NUMBER = {3},
PAGES = {7847--7852},
URL = {http://www.techscience.com/CJU/v22n3/61276},
ISSN = {1488-5581},
ABSTRACT = {Several abstracts presented at the 2015 European 
Association of Urology Meeting highlighted new 
developments in hormone therapy for prostate cancer 
management. One abstract described how the luteinizing 
hormone-releasing hormone (LHRH)/gonadotropin-releasing hormone (GnRH) agonist leuprolide, but not 
the LHRH/GnRH antagonist degarelix, induced plaque 
instability in a mouse model. A second abstract showed that 
in patients with a history of severe cardiovascular disease, 
degarelix was associated with fewer cardiovascular events 
than treatment with an LHRH agonist. A third abstract 
showed how primary androgen-deprivation therapy was 
linked with increased all-cause mortality in a US registry. 
A fourth abstract showed that in the ANAMEN study, 
cognitive performance was not significantly affected by 
6 months of treatment with GnRH agonists. Last, a fifth 
abstract showed that low-dose prednisone, with or without 
abiraterone, was associated with an overall low incidence 
of corticosteroid-associated adverse events.},
DOI = {}
}